Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Gains from Sales and Divestitures: 2019-2025

Historic Gains from Sales and Divestitures for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $19,505.

  • Fulcrum Therapeutics' Gains from Sales and Divestitures fell 12.64% to $19,505 in Q3 2025 from the same period last year, while for Sep 2025 it was $19,505, marking a year-over-year decrease of 12.64%. This contributed to the annual value of $22,326 for FY2024, which is 23.05% up from last year.
  • According to the latest figures from Q3 2025, Fulcrum Therapeutics' Gains from Sales and Divestitures is $19,505, which was down 0.00% from $19,505 recorded in Q2 2025.
  • Fulcrum Therapeutics' 5-year Gains from Sales and Divestitures high stood at $69,833 for Q4 2021, and its period low was $5,496 during Q1 2023.
  • In the last 3 years, Fulcrum Therapeutics' Gains from Sales and Divestitures had a median value of $18,144 in 2023 and averaged $17,134.
  • In the last 5 years, Fulcrum Therapeutics' Gains from Sales and Divestitures crashed by 85.43% in 2022 and then skyrocketed by 110.15% in 2024.
  • Fulcrum Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $69,833 in 2021, then plummeted by 85.43% to $10,174 in 2022, then soared by 78.34% to $18,144 in 2023, then grew by 23.05% to $22,326 in 2024, then declined by 12.64% to $19,505 in 2025.
  • Its last three reported values are $19,505 in Q3 2025, $19,505 for Q2 2025, and $11,003 during Q1 2025.